

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

UNKNOWN

HOM ET AL.

09/816,876

Group Art Unit:

1645

MARCH 23, 2001

Docket:

13615.1USU2

Title:

METHODS TO TREAT ALZHEIMER'S DISEASE

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on July 12, 2001.

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

☐ Transmittal Sheet in duplicate containing Certificate of Mailing

☐ Information Disclosure Statement, Form 1449, 104 References

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903 612.332.5300

PATENT TRADEMARK OFFICE

Name: Matthew A. Doscotch

Reg. No.: P-48,957

MAD:pll



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

HOM ET AL.

Examiner:

UNKNOWN

Serial No.:

09/816,876

Group Art Unit:

1645-

Filed:

MARCH 23, 2001

Docket No.:

13615.JUSU2

Title:

METHODS TO TREAT ALZHEIMER'S DISEASE

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class peail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on July 2001.

By: angel alson

## INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the Consideration of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted, MERCHANT & GOULD P.C. P.O. Box 2903 Minneapolis, MN 55402-0903 612.371.5271

Name: Matthew A. Doscotch

Reg. No. P-48,957

MAD:pll

Date: July 19, 2001

next official communication.

23552
PATENT TRADEMARK OFFICE

2

FORM SALES TO SALES T

NEORMATION DISCLOSURE STATEMENT .

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.1USU2

Filing Date: 03/23/2001

Application Number:

09/816,876

Applicant: HOM ET AL.

Group Art Unit: 1645

H 1600/29

ADEMAS!	· <u>·</u>				<u> </u>	
	_		U.S. PATENT DOCUMENT	`S		
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-	4,224,179	09/23/1980	Schneider			
	4,231,877	11/04/1980	Yamauchi et al.			
	4,235,871	11/25/1980	Papahadjopoulos et al.			
	4,247,411	01/27/1981	Vanlerberghe et al.			
	4,394,448	07/19/1983	Szoka, Jr. et al.		-	
	4,399,216	08/16/1983	Axel et al.			
	4,668,770	05/26/1987	Boger et al.			
	4,673,567	06/16/1987	Jizomoto			
	4,676,980	06/30/1987	Segal et al.			
	4,736,866	04/12/1988	Leder et al.			
	4,753,788	06/28/1988	Gamble			
	4,814,270	03/21/1989	Piran		-	
	4,816,567	03/28/1989	Cabilly et al.			
	4,870,009	09/26/1989	Evans et al.			
···	4,880,781	11/14/1989	Hester, Jr. et al.			
	4,897,355	01/30/1990	Eppstein et al.			
	5,010,182	04/23/1991	Brake et al.			
	5,145,684	09/08/1992	Liversidge et al.			
	5,162,538	11/10/1992	Voges et al.			
	5,250,565	10/05/1993	Brooks et al.			
	5,364,934	11/15/1994	Drayna et al.	1		
	5,374,652	12/20/1994	Buzzetti et al.			
	5,376,542	12/27/1994	Schlegal			
,	5,475,138	12/12/1995	Pal et a.			
	5,602,169	02/11/1997	Hewawasam et al.		·	
	5,602,175	02/11/1997	Talley et al.			
	5,625,031	04/29/1997	Webster et al.			
	5,631,405	05/20/1997	Pal et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

(Use several sheets if necessary)

V& JUEMA	5,663,200	09/02/1997	Bold et al.		
	5,708,004	01/13/1998	Tailey et al.		
	5,733,882	03/31/1998	Carr et al.		
	5,760,076	06/02/1998	Vazquez et al.		
	5,807,891	09/15/1998	Bold et al.		
	5,831,117	11/03/1998	Ng et al.		
	5,849,911	12/15/1998	Fassler et al.		
	5,922,770	07/13/1999	Peschke et al.		-
	5,935,976	08/10/1999	Bold et al.		
	6,013,658	01/11/2000	Lau et al.		
	6,045,829	04/04/2000	Liversidge et al.		

Filing Date: 03/23/2001

## FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	· SUBCLASS	TRANSLATION	
					YES	NO
 3 610 593 A1	10/01/1987	DE with English abstract				
3 721 855 A1	09/22/1988	DE with English abstract				
4 003 575 A1	08/08/1991	DE with English abstract				
0 036 776 A2	09/30/1981	EP				
0 073 657 A1	03/09/1983	EP				
0 117 058 A2	08/29/1984	ЕР				
0 117 060 A2	08/29/1984	EP				
0 173 441 A1	05/03/1986	EP			-	
0 209 897 A2	01/28/1987	EP				
0 212 903 B1	03/04/1987	EP				
0 264 106 B1	04/20/1988	EP				
0 274 259 B1	07/13/1988	EP				
 0 320 205 A1	06/14/1989	EP				
0 337 714 A2	10/18/1989	EP				
0 362 179 A2	04/04/1990	EP				
0 372 537 A3	06/13/1990	EP with English abstract				

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Group Art Unit: 1645

Pate Mailed: July 4, 2001	s	heet 3 of 5	TEQ.		7
FORMATION DISCLOSURE STATEMENT	Docket Number: 13615.1USU2	Application Number: 09/816,876	CENT	שער יי	EC
IN AN APPLICATION	Applicant: HOM ET AL.	•	33	Н	<u>"   </u>
(Use several sheets if necessary)	Filing Date: 03/23/2001	Group Art Unit: 1645	8	20	<b>&gt;</b>

GAUFMAY"								<u>ğ</u> _
	0 437 729 A	2	07/24/1991	EP with English abstract				
	0 609 625 A	1	08/10/1994	EP				
	2 203740 A		10/26/1988	GB				
	2 211 504 A		07/05/1989	GB				
	62-246546		10/27/1987	JP with English abstract				
	7-126286		05/16/1995	JP with English abstract				
	WO 87/0298	6	05/21/1987	PCT				
	WO 87/0434	9	07/30/1987	PCT				
-	WO 87/0533	0	09/11/1987	PCT				
	WO 89/0016	1	01/12/1989	PCT				
	WO 89/0148	8	02/23/1989	PCT				
	WO 89/0585	9	06/29/1989	PCT				
	WO 90/1364	6	11/15/1990	PCT with English abstract	-			
	WO 91/0036	0	01/10/1991	PCT				
	WO 92/0075	0	01/23/1992	PCT				
	WO 92/1749	0	10/15/1992	PCT				
	WO 92/2037	3	11/26/1992	PCT				
	WO 93/0205	7	02/04/1993	PCT				
	WO 93/0882	9	05/13/1993	PCT				
	WO 93/1700	3	09/02/1993	PCT				
	WO 97/3007	2	08/21/1997	PCT				
	WO 98/2940	1	07/09/1998	PCT				
	WO 98/3379	5	08/06/1998	PCT				,
	WO 98/5034	2	11/12/1998	PCT				
	WO 99/4126	6	08/19/1999	PCT				
	WO 99/5429	3	10/28/1999	PCT with English abstract				
	WO 01/1038	7 A2	02/15/2001	PCT				
		ОТН	ER DOCUMEN	TS (Including Author, Title, Dat	e, Pertinent Page	s, Etc.)		
				no-Alcohol Dipeptide Analogue rahedron Letters, Vol. 28, No. 4			ile Isostere fro the	evelopm

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

09/816,876

WALLEMAKE.

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: HOM ET AL.

Docket Number:

13615.1USU2

Filing Date: 03/23/2001 Group Art Unit: 1645

Diederich, A. et al., "Stereoselective Synthesis of a Hydroxyethylene Dipeptide Isostere", <i>Tetrahedron Letters</i> , Vol. 34, No. 39, pp. 6169 - 6172 (September 24, 1993)
Dragovich, P. et al., "Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure—Activity Studies of Ketomethylene-Containing Peptidomimetics", <i>J. Med. Chem.</i> , Vol. 42., No. 7, pp. 1203 - 1212 (April 8, 1999)
Ghosh, A. et al., "Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)", J. Am. Chem. Soc., Vol. 122, No. 14, pp. 3522 - 3523 (April 12, 2000)
Gould, P., "Salt selection for basic drugs", <i>International Journal of Pharmaceutics</i> , Vol. 33, Nos. 1 -3, pp, 201 - 217 (November 1986)
Greene, T. et al., "Protective Groups in Organic Synthesis", Second Edition, <i>John Wiley &amp; Sons, Inc.</i> , Ch. 7, Protection for the Amino Group: Cabamates, pp. 327 - 335 (1991).
Henning, R., "A. Synthetic Routes to Different Classes of Natural Products and Analogs Thereof", Organic Synthesis Highlights II, Edited by Herbert Waldmann, VCH Publishers, New York, NY, pp. 251 - 259 (1995)
Hon, Y-S et al., "The Studies of Metal Ion Catalyzed Carbon-Hydrogen Insertion of α- Alkoxy- α' - Diazoketones Derived from Mandelic and Lactic Acids", <i>Heterocycles</i> , Vol. 31, No. 10, pp. 1745 - 1750 (1990)
Hong, L. et al., "Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor", <i>Science</i> , Vol. 290, No. 5489, pp. 150 -153 (October 6, 2000)
Kaldor, S. et al., "Isophthalic Acid Derivatives: Amino Acid Surrogates for the Inhibition of HIV-1 Protease" Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 7, pp. 721 - 726 (April 6, 1995)
Larock, R., "Comprehensive Organic Transformations – A Guide to Functional Group Preparations", VCH Publishers, Inc., pp. 972 - 985 (1989)
Li, Y. et al., "Photoactivated γ-secretase inhibitors directed to the active site covalently label presentlin 1", <i>Nature</i> Vol. 405, No. 6787, pp. 689 - 694 (June 8, 2000)
Luly, J. et al., "A Synthesis of Protected Aminoalkyl Epoxides from α-Amino Acids", J. Org. Chem., Vol. 52., No. 8., pp. 1487 - 1492 (April 17, 1987)
Martin, S. et al., "Application of AlMe3-Mediated Amidation Reactions to Solution Phase Peptide Synthesis", Tetrahedron Letters, Vol. 39, pp. 1517 - 1520 (1998)
Moersch, G.W. et al., "The Synthesis of x-Hydroxycarboxylic Acids by Aeration of Lithiated Carboxylic Acids in Tetrahydrofuran Solution", <i>International Journal of Methods in Synthetic Organic Chemistry</i> Vol. 12, pp. 647 - 648 (December 1971)
Sabbagh, M. et al., "β-Amyloid and Treatment Opportunities for Alzheimer's Disease", Alzheimer's Disease Review 3, pp. 1 - 19 (1997)
Sakurai, M. et al., "A New Synthetic Route for the γ-Lactone Precursors of Hydroxyethylene Dipeptide Isosteres", Tetrahedron Letters", Vol. 34, No. 37, pp. 5939 - 5942 (September 10, 1993)
Sakurai, M. et al., "Studies of HIV-1 Protease Inhibitors. II. Incorporation of Four Types of Hydroxyethylene Dipeptide Isosteres at the Scissile Site of Substrate Sequences", Chem. Pharm. Bull, Vol. 41, No. 8., pp. 1378 - 1386 (1993)
Selkoe, D., "Translating cell biology into therapeutic advances in Alzheimer's disease", <i>Nature</i> , Supplement to Vol. 399, No. 6733, pp. A23 - A31 (June 24, 1999)
Shibata, N. et al., "An Expeditious Synthesis of (2R,3S)- 3-tert-Butoxycarbonylamino-1-isobutylamino-4phenyl-2-butanol, a Key Building Block of HIV Protease Inhibitors", Tetrahedron Letters, Vol. 38, No. 4, pp. 619 - 620 (January 27, 1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

X	7				RMATION DISCLOSURE STATEMENT	Docket Number: Application Number: 13615.1USU2 09/816,876			
	JL 27 2001		<b>C9</b>	IN AN APPLICATION	Applicant: HOM ET AL.				
		·		e <sup>u</sup>	(Use several sheets if necessary)	Filing Date: 03/23/2001	Group Art Unit: 1645		
E	'```	)E'sa	' رخه						

Journal of Medicinal Chemistry, Vol. 38, No. 4, pp. 581 - 584 (February 17, 1995)

Vazquez, M. et al., "Inhibitors of HIV-1-Protease Containing the Novel and Potent (R)-(Hydroxyethyl)sulfonamide Isostere",

23552
PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.